{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T18:07:34Z","timestamp":1791828454856,"version":"4.3.4"},"reference-count":70,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003056","name":"Ente Cassa di Risparmio di Firenze","doi-asserted-by":"publisher","award":["ECR 2016.0774"],"award-info":[{"award-number":["ECR 2016.0774"]}],"id":[{"id":"10.13039\/501100003056","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011665","name":"Deanship of Scientific Research, King Saud University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.ejmech.2018.10.068","type":"journal-article","created":{"date-parts":[[2018,11,2]],"date-time":"2018-11-02T14:12:43Z","timestamp":1541167963000},"page":"147-160","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":97,"special_numbering":"C","title":["Enhancement of the tail hydrophobic interactions within the carbonic anhydrase IX active site via structural extension: Design and synthesis of novel N-substituted isatins-SLC-0111 hybrids as carbonic anhydrase inhibitors and antitumor agents"],"prefix":"10.1016","volume":"162","author":[{"given":"Wagdy M.","family":"Eldehna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud F.","family":"Abo-Ashour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3342-702X","authenticated-orcid":false,"given":"Alessio","family":"Nocentini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radwan S.","family":"El-Haggar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Bua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Bonardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara T.","family":"Al-Rashood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghada S.","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Gratteri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hatem A.","family":"Abdel-Aziz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4262-0323","authenticated-orcid":false,"given":"Claudiu T.","family":"Supuran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2018.10.068_bib1","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/nrd2467","article-title":"Carbonic anhydrases: novel therapeutic applications for inhibitors and activators","volume":"7","author":"Supuran","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2018.10.068_bib2","doi-asserted-by":"crossref","first-page":"759","DOI":"10.3109\/14756366.2012.672983","article-title":"Structure-based drug discovery of carbonic anhydrase inhibitors","volume":"27","author":"Supuran","year":"2012","journal-title":"J.\u00a0Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.10.068_bib3","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3109\/14756366.2015.1122001","article-title":"How many carbonic anhydrase inhibition mechanisms exist?","volume":"31","author":"Supuran","year":"2016","journal-title":"J.\u00a0Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.10.068_bib4a","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.4155\/fmc.11.69","article-title":"Carbonic anhydrase inhibitors and activators for novel therapeutic applications","volume":"3","author":"Supuran","year":"2011","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.ejmech.2018.10.068_bib4b","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1517\/13543776.2013.794788","article-title":"Antiglaucoma carbonic anhydrase inhibitors: a patent review","volume":"23","author":"Masini","year":"2013","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejmech.2018.10.068_bib5","doi-asserted-by":"crossref","first-page":"3437","DOI":"10.1073\/pnas.0813178106","article-title":"Pathogenesis of retinitis pigmentosa associated with apoptosis-inducing mutations in carbonic anhydrase IV","volume":"106","author":"Datta","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejmech.2018.10.068_bib6","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/nrd3554","article-title":"Interfering with pH regulation in tumours as a therapeutic strategy","volume":"10","author":"Neri","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2018.10.068_bib7","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1517\/13543776.2013.798648","article-title":"Anticancer carbonic anhydrase inhibitors: a patent review (2008\u22122013)","volume":"23","author":"Monti","year":"2013","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejmech.2018.10.068_bib8","doi-asserted-by":"crossref","first-page":"84","DOI":"10.18632\/oncotarget.422","article-title":"Recent developments in targeting carbonic anhydrase IX for cancer therapeutics","volume":"3","author":"McDonald","year":"2012","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2018.10.068_bib9","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3390\/metabo7030048","article-title":"Carbonic anhydrase inhibition and the management of hypoxic tumors","volume":"7","author":"Supuran","year":"2017","journal-title":"Metabolites"},{"key":"10.1016\/j.ejmech.2018.10.068_bib10","doi-asserted-by":"crossref","first-page":"3364","DOI":"10.1158\/0008-5472.CAN-10-4261","article-title":"Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors","volume":"71","author":"Lou","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2018.10.068_bib11","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1517\/13543776.2013.798648","article-title":"Anticancer carbonic anhydrase inhibitors: a patent review (2008 \u2013 2013)","volume":"23","author":"Monti","year":"2013","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejmech.2018.10.068_bib12","doi-asserted-by":"crossref","first-page":"5210","DOI":"10.1038\/onc.2012.550","article-title":"Targeting carbonic anhydrase IX depletes breast cancer stem cells within the hypoxic niche","volume":"32","author":"Lock","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2018.10.068_bib13","first-page":"1","article-title":"Inhibition of carbonic anhydrase IX targets primary tumors, metastases, and cancer stem cells: three for the price of one","author":"Supuran","year":"2018","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2018.10.068_bib14","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.bmc.2013.11.016","article-title":"Combining the tail and the ring approaches for obtaining potent and isoform-selective carbonic anhydrase inhibitors: solution and X-ray crystallographic studies","volume":"22","author":"Bozdag","year":"2014","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.10.068_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejmech.2018.04.016","article-title":"Dual-tail arylsulfone-based benzenesulfonamides differently match the hydrophobic and hydrophilic halves of human carbonic anhydrases active sites: selective inhibitors for the tumor-associated hCA IX isoform","volume":"152","author":"Ibrahim","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.10.068_bib16","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1016\/j.bmc.2017.02.037","article-title":"Synthesis of bulky-tailed sulfonamides incorporating pyrido [2, 3-d][1, 2, 4] triazolo [4, 3-a] pyrimidin-1 (5H)-yl) moieties and evaluation of their carbonic anhydrases I, II, IV and IX inhibitory effects","volume":"25","author":"Fares","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.10.068_bib17","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.3109\/14756366.2015.1115401","article-title":"7-Aryl-triazolyl-substituted sulfocoumarins are potent, selective inhibitors of the tumor-associated carbonic anhydrase IX and XII","volume":"31","author":"Nocentini","year":"2016","journal-title":"J.\u00a0Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.10.068_bib18","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.ejmech.2016.01.001","article-title":"Development of certain new 2-substituted-quinazolin-4-yl-aminobenzenesulfonamide as potential antitumor agents","volume":"109","author":"Alafeefy","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.10.068_bib19","doi-asserted-by":"crossref","first-page":"6955","DOI":"10.1016\/j.bmc.2015.09.041","article-title":"Click-tailed coumarins with potent and selective inhibitory action against the tumorassociated carbonic anhydrases IX and XII","volume":"23","author":"Nocentini","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.10.068_bib20","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.bmc.2013.11.016","article-title":"Combining the tail and the ring approaches for obtaining potent and isoform-selective carbonic anhydrase inhibitors: solution and X-ray crystallographic studies","volume":"22","author":"Bozdag","year":"2014","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.10.068_bib21","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/biof.1408","article-title":"Isatin, an endogenous nonpeptide biofactor: a review of its molecular targets, mechanisms of actions, and their biomedical implications","volume":"44","author":"Medvedev","year":"2018","journal-title":"Biofactors"},{"key":"10.1016\/j.ejmech.2018.10.068_bib22","doi-asserted-by":"crossref","first-page":"451","DOI":"10.4172\/2161-0444.1000179","article-title":"Isatins: a diversity orientated biological profile","volume":"4","author":"Kidwai","year":"2014","journal-title":"Med. Chem."},{"key":"10.1016\/j.ejmech.2018.10.068_bib23","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1158\/1078-0432.CCR-06-2328","article-title":"Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma","volume":"13","author":"Goodman","year":"2007","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.ejmech.2018.10.068_bib24","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s40265-014-0335-0","article-title":"Nintedanib: first global approval","volume":"75","author":"McCormack","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2018.10.068_bib25","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1080\/14756366.2017.1279155","article-title":"Synthesis and in\u00a0vitro anti-proliferative activity of some novel isatins conjugated with quinazoline\/phthalazine hydrazines against triple-negative breast cancer MDA-MB-231 cells as apoptosis-inducing agents","volume":"32","author":"Eldehna","year":"2017","journal-title":"J.\u00a0Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.10.068_bib26","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1080\/14756366.2017.1417276","article-title":"One-pot three-component synthesis of novel spirooxindoles with potential cytotoxic activity against triple-negative breast cancer MDAMB-231 cells","volume":"33","author":"Eldehna","year":"2018","journal-title":"J.\u00a0Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.10.068_bib27","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.2147\/DDDT.S140164","article-title":"Isatin-benzoazine molecular hybrids as potential antiproliferative agents: synthesis and in\u00a0vitro pharmacological profiling","volume":"11","author":"Abdel-Aziz","year":"2017","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.ejmech.2018.10.068_bib28","first-page":"7","article-title":"Synthesis, crystal structure, and biological activity of cis\/trans amide rotomers of (Z)-N'-(2-Oxoindolin-3-ylidene)formohydrazide","volume":"2014","author":"Abdel-Aziz","year":"2014","journal-title":"J.\u00a0Chem."},{"key":"10.1016\/j.ejmech.2018.10.068_bib29","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.3390\/molecules23061420","article-title":"Novel thiazolidinone\/thiazolo [3, 2-a] benzimidazolone-isatin conjugates as apoptotic anti-proliferative agents towards breast cancer: one-pot synthesis and in\u00a0vitro biological evaluation","volume":"23","author":"El-Naggar","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2018.10.068_bib30","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1080\/14756366.2018.1462802","article-title":"Synthesis and biological evaluation of certain hydrazonoindolin-2-one derivatives as new potent anti-proliferative agents","volume":"33","author":"Eldehna","year":"2018","journal-title":"J.\u00a0Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.10.068_bib31","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ejmech.2018.07.054","article-title":"Novel hydrazido benzenesulfonamides-isatin conjugates: synthesis, carbonic anhydrase inhibitory activity and molecular modeling studies","volume":"157","author":"Abo-Ashour","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.10.068_bib32","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.bioorg.2018.09.007","article-title":"Tumor-associated carbonic anhydrase isoform IX and XII inhibitory properties of certain isatin-bearing sulfonamides endowed with in\u00a0vitro anticancer activity towards colon cancer","volume":"81","author":"Eldehna","year":"2018","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2018.10.068_bib33","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.ejmech.2015.09.021","article-title":"Isatin-pyrazole benzenesulfonamide hybrids potently inhibit tumor-associated carbonic anhydrase isoforms IX and XII","volume":"103","author":"Ibrahim","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.10.068_bib34","doi-asserted-by":"crossref","first-page":"6493","DOI":"10.1039\/C5OB00688K","article-title":"Discovery of novel isatin-based sulfonamides with potent and selective inhibition of the tumor associated carbonic anhydrase isoforms IX and XII","volume":"13","author":"G\u00fczel-Akdemir","year":"2015","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.ejmech.2018.10.068_bib35","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.ejmech.2017.01.017","article-title":"Novel indolin-2-one-based sulfonamides as carbonic anhydrase inhibitors: synthesis, in\u00a0vitro biological evaluation against carbonic anhydrases isoforms I, II, IV and VII and molecular docking studies","volume":"127","author":"Eldehna","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.10.068_bib36","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.ejmech.2017.07.073","article-title":"Novel 4\/3-((4-oxo-5-(2-oxoindolin-3-ylidene) thiazolidin-2-ylidene) amino) benzenesulfonamides: synthesis, carbonic anhydrase inhibitory activity, anticancer activity and molecular modelling studies","volume":"139","author":"Eldehna","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.10.068_bib37","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ejmech.2016.01.030","article-title":"Amido\/ureidosubstituted benzenesulfonamides-isatin conjugates as low nanomolar\/subnanomolar inhibitors of the tumor-associated carbonic anhydrase isoform XII","volume":"110","author":"Eldehna","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.10.068_bib38a","doi-asserted-by":"crossref","first-page":"3714","DOI":"10.1016\/j.bmc.2017.05.029","article-title":"Novel sulfonamide-containing 2-indolinones that selectively inhibit tumor-associated alpha carbonic anhydrases","volume":"25","author":"Karal\u0131","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.10.068_bib38b","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1080\/14756366.2016.1235042","article-title":"Isatin: a privileged scaffold for the design of carbonic anhydrase inhibitors","volume":"32","author":"Melis","year":"2017","journal-title":"J.\u00a0Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.10.068_bib39","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3109\/14756369809035830","article-title":"Carbonic anhydrase inhibitor: ureido and thioureido derivatives of aromatic sulfonamides possessing increased affinities for isozymes I. A novel route to 2, 5-disubstituted-1,3,4-thidiazoles via thioureas and their interaction with isozymes I, II and IV","volume":"13","author":"Scozzafava","year":"1998","journal-title":"J.\u00a0Enzym. Inhib."},{"key":"10.1016\/j.ejmech.2018.10.068_bib40","doi-asserted-by":"crossref","first-page":"4681","DOI":"10.1016\/j.bmcl.2012.05.083","article-title":"Ureido-substituted sulfamates show potent carbonic anhydrase IX inhibitory and antiproliferative activities against breast cancer cell lines","volume":"22","author":"Winum","year":"2012","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2018.10.068_bib41","doi-asserted-by":"crossref","first-page":"6768","DOI":"10.1016\/j.bmc.2014.10.041","article-title":"Inhibition studies of new ureido-substituted sulfonamides incorporating a GABA moiety against human carbonic anhydrase isoforms I\u2013XIV","volume":"22","author":"Ceruso","year":"2014","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.10.068_bib42","doi-asserted-by":"crossref","first-page":"5619","DOI":"10.1016\/j.bmc.2015.07.024","article-title":"Synthesis and carbonic anhydrase I, II, IX and XII inhibitory activity of sulfamates incorporating piperazinyl-ureido moieties","volume":"23","author":"Congiu","year":"2015","journal-title":"Bioorg. Med. Chem. Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.10.068_bib43","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3109\/14756366.2015.1014477","article-title":"Synthesis and inhibition potency of novel ureido benzenesulfonamides incorporating GABA as tumor-associated carbonic anhydrase IX and XII inhibitors","volume":"31","author":"Ceruso","year":"2016","journal-title":"J.\u00a0Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.10.068_bib44","doi-asserted-by":"crossref","first-page":"901","DOI":"10.3109\/14756366.2014.986118","article-title":"Inhibition of carbonic anhydrase isoforms I, II, IX and XII with Schiff's bases incorporating iminoureido moieties","volume":"30","author":"Singasane","year":"2015","journal-title":"J.\u00a0Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.10.068_bib45","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1021\/jm101541x","article-title":"Ureido-substituted benzenesulfonamides potently inhibit carbonic anhydrase IX and show antimetastatic activity in a model of breast cancer metastasis","volume":"54","author":"Pacchiano","year":"2011","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.10.068_bib46","unstructured":"Safety Study of SLC\u20130111 in Subjects with advanced solid tumours. Available from https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT02215850?term=SLC_0111&rank=1."},{"key":"10.1016\/j.ejmech.2018.10.068_bib47","doi-asserted-by":"crossref","first-page":"10070","DOI":"10.1039\/C6RA26779C","article-title":"Conformational stabilization of isatin Schiff bases\u2013biologically active chemical probes","volume":"7","author":"Smirnov","year":"2017","journal-title":"RSC Adv."},{"key":"10.1016\/j.ejmech.2018.10.068_bib48","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1016\/S0021-9258(18)62326-9","article-title":"The carbon dioxide hydration activity of carbonic anhydrase I. Stop-flow kinetic studies on the native human isoenzymes B and C","volume":"246","author":"Khalifah","year":"1971","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2018.10.068_bib49","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s11307-015-0885-x","article-title":"Evaluation of CAIX and CAXII expression in breast cancer at varied O2 levels: CAIX is the superior surrogate imaging biomarker of tumor hypoxia","volume":"18","author":"Tafreshi","year":"2016","journal-title":"Mol. Imag. Biol."},{"key":"10.1016\/j.ejmech.2018.10.068_bib50","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","article-title":"Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays","volume":"65","author":"Mosmann","year":"1983","journal-title":"J.\u00a0Immunol. Methods"},{"key":"10.1016\/j.ejmech.2018.10.068_bib51","first-page":"2597","article-title":"Modified annexin V\/propidium iodide apoptosis assay for accurate assessment of cell death","volume":"50","author":"Rieger","year":"2011","journal-title":"JoVE: JoVE"},{"key":"10.1016\/j.ejmech.2018.10.068_bib52","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/386671a0","article-title":"Mechanisms of angiogenesis","volume":"386","author":"Risau","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2018.10.068_bib53","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1016\/j.cellsig.2007.05.013","article-title":"Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition","volume":"19","author":"Holmes","year":"2007","journal-title":"Cell. Signal."},{"key":"10.1016\/j.ejmech.2018.10.068_bib54","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ejmech.2015.05.040","article-title":"Indoline ureas as potential anti-hepatocellular carcinoma agents targeting VEGFR-2: synthesis, in\u00a0vitro biological evaluation and molecular docking","volume":"100","author":"Eldehna","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.10.068_bib55","doi-asserted-by":"crossref","first-page":"10692","DOI":"10.1021\/acs.jmedchem.6b01389","article-title":"Benzenesulfonamides incorporating flexible triazole moieties are highly effective carbonic anhydrase inhibitors: synthesis and kinetic, crystallographic, computational, and intraocular pressure lowering investigations","volume":"59","author":"Nocentini","year":"2016","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.10.068_bib56","doi-asserted-by":"crossref","first-page":"9004","DOI":"10.1021\/acs.jmedchem.5b01343","article-title":"Efficient expression and crystallization system of cancer-associated carbonic anhydrase isoform IX","volume":"58","author":"Leitans","year":"2015","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.10.068_bib57","doi-asserted-by":"crossref","first-page":"762","DOI":"10.3390\/molecules21060762","article-title":"Synthesis and cytotoxic activity of biphenylurea derivatives containing indolin-2-one moieties","volume":"21","author":"Eldehna","year":"2016","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2018.10.068_bib58","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1080\/14756366.2017.1421181","article-title":"Novel [(3-indolylmethylene) hydrazono] indolin-2-ones as apoptotic anti-proliferative agents: design, synthesis and in\u00a0vitro biological evaluation","volume":"33","author":"Eldehna","year":"2018","journal-title":"J.\u00a0Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.10.068_bib59","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0181241","article-title":"New hydrazonoindolin-2-ones: synthesis, exploration of the possible anti-proliferative mechanism of action and encapsulation into PLGA microspheres","volume":"12","author":"Attia","year":"2017","journal-title":"PloS One"},{"key":"10.1016\/j.ejmech.2018.10.068_bib60","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.ejmech.2015.08.017","article-title":"Spirooxindole-derived morpholine-fused-1, 2, 3-triazoles: design, synthesis, cytotoxicity and apoptosis inducing studies","volume":"102","author":"Senwar","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.10.068_bib61","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1021\/acschemneuro.5b00150","article-title":"Identification of the first highly subtype-selective inhibitor of human GABA transporter GAT3","volume":"6","author":"Damgaard","year":"2015","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.ejmech.2018.10.068_bib62","doi-asserted-by":"crossref","first-page":"5380","DOI":"10.1021\/acs.jmedchem.8b00625","article-title":"Discovery of \u03b2-adrenergic receptors blocker-carbonic anhydrase inhibitor hybrids for multitargeted antiglaucoma therapy","volume":"61","author":"Nocentini","year":"2018","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.10.068_bib63","doi-asserted-by":"crossref","first-page":"7840","DOI":"10.1002\/chem.201800941","article-title":"Deciphering the mechanism of human carbonic anhydrases inhibition with sulfocoumarins: computational and experimental studies","volume":"24","author":"Nocentini","year":"2018","journal-title":"Chemistry"},{"key":"10.1016\/j.ejmech.2018.10.068_bib64","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.bioorg.2018.07.027","article-title":"Synthesis of novel isoindoline-1,3-dione-based oximes and benzenesulfonamide hydrazones as selective inhibitors of the tumor-associated carbonic anhydrase IX","volume":"80","author":"Abdel-Aziz","year":"2018","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2018.10.068_bib65","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1021\/acsmedchemlett.7b00399","article-title":"Discovery of new sulfonamide carbonic anhydrase IX inhibitors incorporating nitrogenous bases","volume":"8","author":"Nocentini","year":"2017","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2018.10.068_bib66","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1080\/14756366.2017.1414808","article-title":"Carbonic anhydrases from Trypanosoma cruzi and Leishmania donovani chagasi are inhibited by benzoxaboroles","volume":"33","author":"Nocentini","year":"2018","journal-title":"J.\u00a0Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.10.068_bib67","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.3390\/ijms17081221","article-title":"Synthesis, crystal study, and anti-proliferative activity of some 2-benzimidazolylthioacetophenones towards triple-negative breast cancer MDA-MB-468 cells as apoptosis-inducing agents","volume":"17","author":"Abdel-Aziz","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2018.10.068_bib68","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ejmech.2016.02.029","article-title":"Increasing the binding affinity of VEGFR-2 inhibitors by extending their hydrophobic interaction with the active site: design, synthesis and biological evaluation of 1-substituted-4-(4-methoxybenzyl) phthalazine derivatives","volume":"113","author":"Eldehna","year":"2016","journal-title":"Eur. J. Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523418309462?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523418309462?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T13:47:14Z","timestamp":1759326434000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523418309462"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":70,"alternative-id":["S0223523418309462"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2018.10.068","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enhancement of the tail hydrophobic interactions within the carbonic anhydrase IX active site via structural extension: Design and synthesis of novel N-substituted isatins-SLC-0111 hybrids as carbonic anhydrase inhibitors and antitumor agents","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2018.10.068","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}